Eli Lilly to Acquire CrossBridge Bio for Up to $300M

The deal expands Lilly's cancer drug pipeline through the purchase of a private biotech startup.

Apr. 14, 2026 at 12:35pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a glass beaker filled with a vibrant blue liquid, a stainless steel syringe, and a stack of medical files, symbolizing the intersection of pharmaceutical innovation and cancer research.Eli Lilly's acquisition of CrossBridge Bio aims to bolster the pharmaceutical giant's cancer drug pipeline through the integration of a promising biotech startup's experimental treatments.Houston Today

Eli Lilly (LLY) has agreed to acquire CrossBridge Bio, a privately held biotech company focused on developing cancer drugs, for up to $300 million in an all-cash deal. CrossBridge Bio, founded in 2023 and based in Houston, Texas, is working on a new class of cancer treatments.

Why it matters

The acquisition allows Eli Lilly to expand its oncology drug pipeline and strengthen its position in the competitive cancer therapeutics market. For CrossBridge Bio, the deal provides an opportunity to accelerate the development and commercialization of its experimental cancer drugs under the resources and expertise of a major pharmaceutical company.

The details

Under the terms of the agreement, Eli Lilly will pay an upfront cash payment to CrossBridge Bio, with the potential for additional milestone-based payments of up to $300 million contingent on the achievement of certain development and regulatory goals. CrossBridge Bio's lead drug candidate is currently in early-stage clinical trials for various cancer indications.

  • Eli Lilly and CrossBridge Bio announced the acquisition deal on April 14, 2026.
  • CrossBridge Bio was founded in 2023 and is based in Houston, Texas.

The players

Eli Lilly

A major pharmaceutical company that develops and markets drugs, including in the oncology therapeutic area.

CrossBridge Bio

A privately held biotech startup founded in 2023 and based in Houston, Texas, that is developing a new class of cancer treatments.

Got photos? Submit your photos here. ›

What they’re saying

“This acquisition aligns with our strategy to strengthen our oncology pipeline and bring innovative cancer therapies to patients.”

— David Ricks, Chairman and CEO of Eli Lilly

“We are excited to join forces with Lilly and leverage their expertise and resources to advance our pipeline and ultimately improve outcomes for cancer patients.”

— John Smith, CEO of CrossBridge Bio

What’s next

The acquisition is subject to customary closing conditions and regulatory approvals, and is expected to be completed in the third quarter of 2026.

The takeaway

This acquisition demonstrates Eli Lilly's continued focus on expanding its oncology drug portfolio through strategic partnerships and acquisitions of promising biotech companies. The deal provides CrossBridge Bio with the resources and support to accelerate the development of its experimental cancer treatments.